Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology ...
AbbVie today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago. AbbVie will present 18 abstracts, ...
AbbVie (NYSE:ABBV) reported first-quarter 2026 results that exceeded its expectations and prompted an increase to full-year ...
AbbVie Inc. raised its full-year profit forecast after quarterly results beat estimates, a sign of confidence amid growing ...
A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical ...
Pfizer has a higher-yielding dividend, but it may not be safe. AbbVie has the better path to growth in 2026. But when you ...
There are still some generous yielders if you know where to look.
Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on BioEquity Watch’s Substack. In ...
StockStory.org on MSN
ABBV Q1 deep dive: Immunology and neuroscience growth, raised full-year outlook
Pharmaceutical company AbbVie (NYSE:ABBV) in Q1 CY2026 as sales rose 4.8% year on year to $13.98 billion. Its non-GAAP profit ...
Johnson & Johnson announced that it entered into a definitive agreement to acquire Atraverse Medical. Regeneron struck a drug pricing deal with the Trump administration to reduce prices on drugs for ...
The laborious process of naming a pharmaceutical takes months and sometimes years of brainstorming, trademark review, legal ...
Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results